Provided by Tiger Trade Technology Pte. Ltd.

IDEAYA Biosciences

31.89
+0.22000.69%
Volume:434.99K
Turnover:13.66M
Market Cap:2.80B
PE:-24.82
High:32.10
Open:31.67
Low:31.00
Close:31.67
52wk High:39.28
52wk Low:13.45
Shares:87.67M
Float Shares:81.82M
Volume Ratio:0.72
T/O Rate:0.53%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-1.2849
EPS(LYR):-1.2849
ROE:-10.92%
ROA:-8.92%
PB:2.73
PE(LYR):-24.82

Loading ...

IDEAYA Biosciences Inc - Initiation of Ide849 Monotherapy Study in Sclc/Nec Targeted by End of 2026

THOMSON REUTERS
·
Feb 17

IDEAYA Biosciences Inc - Preliminary Clinical Data Update From IDEAYA-Sponsored Global Phase 1 Trial of Ide849 Expected by End of 2026

THOMSON REUTERS
·
Feb 17

IDEAYA Biosciences Reports Fourth Quarter and Full Year 2025 Financial Results and Provides a Business Update

THOMSON REUTERS
·
Feb 17

IDEAYA Biosciences Q4 EPS USD -0.94 VS. Ibes Estimate USD -0.97

THOMSON REUTERS
·
Feb 17

IDEAYA Biosciences Joins Virtual Oncology Leadership Summit and Hosts Investor Fireside Chat

Reuters
·
Feb 02

BRIEF-IDEAYA Biosciences Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

Reuters
·
Jan 30

IDEAYA Biosciences Grants Stock Options to New Employee Under Inducement Plan

Reuters
·
Jan 30

IDEAYA Biosciences Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)

THOMSON REUTERS
·
Jan 30

IDEAYA Biosciences Is Maintained at Outperform by RBC Capital

Dow Jones
·
Jan 21

RBC Raises Price Target on IDEAYA Biosciences to $45 From $41, Keeps Outperform, Speculative Risk

MT Newswires Live
·
Jan 21

IDEAYA Biosciences (IDYA) Receives a Buy from Citi

TIPRANKS
·
Jan 14

IDEAYA Biosciences Announces 2026 Pipeline Advancements and Reports $1.1 Billion Cash Position

Reuters
·
Jan 13

Analysts Offer Insights on Healthcare Companies: Medline, Inc. Class A (MDLN) and IDEAYA Biosciences (IDYA)

TIPRANKS
·
Jan 12

Ideaya Biosciences provides business update for 2026

TIPRANKS
·
Jan 12

IDEAYA Biosciences Releases Updated Corporate Presentation

Reuters
·
Jan 12

IDEAYA Biosciences Provides a Business Update and Outlines 2026 Corporate Objectives at the 44TH Annual J.p. Morgan Healthcare Conference

THOMSON REUTERS
·
Jan 12

IDEAYA Biosciences Coverage Assumed by UBS at Buy

Dow Jones
·
Jan 08

IDEAYA Biosciences Is Maintained at Buy by Truist Securities

Dow Jones
·
Jan 06

IDEAYA Biosciences Presents at J.P. Morgan Healthcare Conference

Reuters
·
Jan 05

IDEAYA Biosciences (IDYA): Valuation Check After Key Phase 2/3 Milestone for Darovasertib in Uveal Melanoma

Simply Wall St.
·
Dec 26, 2025